1. A compound having the formula I



I

in which:

Ring A	is (C_3-C_8)-cycloalkanediyl or (C_3-C_8)-cycloalkenediyl, wherein one or more carbon atoms of the (C_3-C_8)-cycloalkanediyl ring or the (C_3-C_8)-cycloalkenediyl ring may be replaced by oxygen atoms;
R1, R2	independently of one another are H, F, Cl, Br, CF_3, OCF_3, (C_1-C_6)-alkyl, O-(C_1-C_6)-alkyl, SCF_3, SF_5, OCF_2-CHF_2, (C_6-C_{10})-aryl, (C_6-C_{10})-aryloxy, OH, NO_2; or
R1 and R2	together with the phenyl, pyridine, 1H-pyrrole, thiophene or furan ring form fused, partially or unsaturated bicyclic (C_6-C_{10})-aryl, (C_5-C_{11})-heteroaryl;
R3	is H, (C_1-C_6)-alkyl, (C_3-C_8)-cycloalkyl, (C_1-C_3)-alkyl-(C_3-C_8)-cycloalkyl, phenyl, (C_1-C_3)-alkyl-phenyl, (C5-C6)-heteroaryl, (C1-C3)-alkyl-(C5-C6)-heteroaryl or (C1-C3)-alkyl which is fully or partially substituted by F;
W	is CH or N if o = 1;
W	is O, S or NR10 if o = 0;
X	is (C_1-C_6)-alkanediyl, where in the alkanediyl group one or more carbon atoms may be replaced by oxygen atoms;
n	is 0-2;
R4	is H or (C_1-C_6)-alkyl;

R5 is H or $(C_1$-$C_6)$-alkyl;

R6 is H, $(C_1$-$C_6)$-alkyl or F;

R7 is H; F; $(C_1$-$C_6)$-alkoxy; $(C_2$-$C_6)$-alkenyl; $(C_2$-$C_6)$-alkynyl; $(C_3$-$C_8)$-cycloalkyl; phenyl which may be unsubstituted or substituted by one or more radicals from the group consisting of hydroxy, $(C_1$-$C_6)$-alkoxy, F and CF_3; $(C_1$-$C_6)$-alkyl which may be unsubstituted or substituted by one or more radicals selected from the group consisting of hydroxyl, phenyl, $(C_5$-$C_{11})$-heteroaryl, $(C_1$-$C_6)$-alkoxy and NR11R12;

with the proviso that R7 is not NR11R12 or $(C_1$-$C_6)$-alkoxy if R6 = F;

R7 and R9 together with the atoms that carry them are pyrrolidine or piperidine if n = 0;

R6 and R7 together with the carbon atom that carries them are $(C_3$-$C_8)$-cycloalkyl;

R8 is H, $(C_1$-$C_6)$-alkyl;

R9 is H, $(C_1$-$C_6)$-alkyl, $(C_2$-$C_6)$-alkenyl, $(C_2$-$C_6)$-alkynyl, $(C_1$-$C_4)$-alkyl-$(C_6$-$C_{10})$-aryl, $(C_1$-$C_4)$-alkyl-$(C_5$-$C_{11})$-heteroaryl, $(C_1$-$C_4)$-alkyl-O-$(C_1$-$C_4)$-alkyl, phenyl-$(C_1$-$C_4)$-alkyl, $(C_5$-$C_6)$-heteroaryl-$(C_1$-$C_4)$-alkyl;

R10 is H, $(C_1$-$C_6)$-alkyl-phenyl, $(C_1$-$C_6)$-alkyl;

R11 is H, $(C_1$-$C_6)$-alkyl-phenyl, $(C_1$-$C_6)$-alkyl;

R12 is H, $(C_1$-$C_6)$-alkyl-phenyl, $(C_1$-$C_6)$-alkyl;

a physiologically acceptable salt of the compound;
a solvate of the compound; or
a physiologically effective derivative of the compound.

2. The compound of Claim 1, in which

Ring A is (C_3-C_8)-cycloalkanediyl or (C_3-C_8)-cycloalkenediyl, wherein one carbon atom of the (C_3-C_8)-cycloalkanediyl ring or the (C_3-C_8)-cycloalkenediyl ring may be replaced by an oxygen atom;

X is (C_1-C_6)-alkanediyl, wherein the C1 or C2 carbon atom (to Ring A) of the alkanediyl group may be replaced by an oxygen atom.

3. The compound of Claim 1, in which

Ring A is cis-cyclohexane-1,3-diyl

R1 is Br, CF_3, OCF_3, (C_1-C_6)-alkyl, O-(C_1-C_6)-alkyl;

R2 is H, (C1-C6)-alkyl, O-(C1-C6)-alkyl or

R1 and R2 together with the phenyl ring form naphthyl;

R3 is CF_3, (C_1-C_6)-alkyl, (C_3-C_8)-cycloalkyl, phenyl;

W is CH if o = 1;

X is CH_2O or CH_2-O-CH_2;

n is 0;

R6 is H or (C_1-C_6)-alkyl;

R7 is (C_1-C_6)-alkyl, where alkyl may be unsubstituted or substituted by phenyl;

R7 and R9 together with the atoms that carry them are pyrrolidine if n = 0;

R6 and R7 together with the carbon atom that carries them are (C_3-C_6)-

cycloalkyl;

R8 is H; and

R9 is H, (C_1-C_6)-alkyl or benzyl.

4. A pharmaceutical composition, comprising the compound of Claim 1 and a pharmaceutically acceptable carrier.

5. The pharmaceutical composition of Claim 4, further comprising an active compound having a favorable effect on a metabolic disorder or disease.

6. The pharmaceutical composition of Claim 4, further comprising an antidiabetic.

7. The pharmaceutical composition of Claim 4, further comprising a lipid modulator.

8. A method for treating and/or preventing a disorder of fatty acid metabolism and/or a glucose utilization disorder in a patient, comprising administering a therapeutically effective amount of the compound of Claim 1 to the patient.

9. A method for treating a disorder in which insulin resistance is involved in a patient, comprising administering a therapeutically effective amount of the compound of Claim 1 to the patient.

10. A method for treating and/or preventing diabetes mellitus and its sequelae in a patient, comprising administering a therapeutically effective amount of the compound of Claim 1 to the patient.

11. A method for treating and/or preventing dyslipidemias and their sequelae in a patient, comprising administering a therapeutically effective amount of the compound of Claim 1 to the patient.

12. A method for treating and/or preventing a disease state or disorder state in a patient associated with a metabolic syndrome, comprising

administering a therapeutically effective amount of the compound of Claim 1 to the patient.

13. The method of Claim 8, further comprising administering in combination at least one further active compound for treating and/or preventing a disorder of the fatty acid metabolism and/or glucose utilization disorder.

14. The method of Claim 9, further comprising administering a at least one further active compound for treating and/or preventing a disorder in which insulin is involved.

15. A process for preparing a pharmaceutical comprising the compmound of Claim 1, comprising the steps of:

(a) mixing the compound with a pharmaceutically acceptable carrier, and;

(b) bringing the mixture into a form suitable for administration.

16. A pharmaceutical composition comprising the compound of Claim 2 and a pharmaceutically acceptable carrier.

17. A method for treating and/or preventing a disorder of fatty acid metabolism and/or a glucose utilization disorder in a patient, comprising administering a therapeutically effective amount of the compound of Claim 2 to the patient.

18. A method for treating a disorder in which insulin resistance is involved in a patient, comprising administering a therapeutically effective amount of the compound of Claim 2 to the patient.

19. A method for treating and/or preventing diabetes mellitus and its sequelae in a patient, comprising administering a therapeutically effective amount of the compound of Claim 2 to the patient.

20. A method for treating and/or preventing dyslipidemias and their sequelae in a patient, comprising administering a therapeutically effective amount of the compound of Claim 2 to the patient.

21. A method for treating and/or preventing a disease state or disorder state in a patient associated with a metabolic syndrome, comprising administering a therapeutically effective amount of the compound of Claim 2 to the patient.

22. A pharmaceutical composition comprising the compound of Claim 3 and a pharmaceutically acceptable carrier.

23. A method for treating and/or preventing a disorder of fatty acid metabolism and/or a glucose utilization disorder in a patient, comprising administering a therapeutically effective amount of the compound of Claim 3 to the patient.

24. A method for treating a disorder in which insulin resistance is involved in a patient, comprising administering a therapeutically effective amount of the compound of Claim 3 to the patient.

25. A method for treating and/or preventing diabetes mellitus and its sequelae in a patient, comprising administering a therapeutically effective amount of the compound of Claim 3 to the patient.

26. A method for treating and/or preventing dyslipidemias and their sequelae in a patient, comprising administering a therapeutically effective amount of the compound of Claim 3 to the patient.

27. A method for treating and/or preventing a disease state or disorder state in a patient associated with a metabolic syndrome, comprising administering a therapeutically effective amount of the compound of Claim 3 to the patient.